Net Income

As GLP-1 drugs dominate, Veru Inc. advances a novel therapy to combat muscle loss, aiming for a new standard of 'quality' weight loss in older adults.

The 90-year-old insurer goes live with Equisoft's SaaS platform, tackling industry-wide tech debt to boost agent efficiency and speed product launches.

With a top industry award, CodaMetrix validates autonomous AI's power to fix healthcare's costly billing woes, reshaping both finances and jobs.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

As AI's power needs skyrocket, GridAI brings in veteran Tim Healy to lead its charge. Can his software-first approach solve the grid's biggest challenge?

The AI firm has fully deployed an AI agent to assist recruiters in live interviews, a move that promises efficiency but raises critical ethical questions.

Beyond Cancer is set to reveal early human trial data for its novel nitric oxide therapy, a move that could expand its parent company into oncology.

Digital asset firm Streamex appoints NYU's Anthony Marciano, signaling a strategic push for institutional credibility and M&A amid financial headwinds.

Nasdaq-listed Zeta Network Group is exploring real-world asset tokenization, signaling a pivotal move beyond Bitcoin for institutional treasury management.

As Aspen Aerogels prepares its Q4 results, investors weigh a challenging 2025 against a booming aerogel market and future EV growth prospects.

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.

A new biotech partnership is accelerating development of a once-daily tablet for hypoparathyroidism, a rare disease currently requiring injections.

Aramark has increased its quarterly dividend, a move reflecting strong financials. But what does it say about its strategy in a changing global market?

With a 90% clinical trial failure rate, BullFrog AI is launching a new tool to help drugmakers make smarter, risk-balanced R&D decisions.

Celcuity prepares for a key fireside chat at Guggenheim's 2026 summit, with investors eyeing crucial updates on its lead cancer drug, gedatolisib.

Automotive seating giant Adient boosts its 2026 forecast, banking on strong North American production and operational gains, despite a reported net loss.

A landmark survey reveals a massive capital rotation as 96% of institutions chase AI and 81% move to private markets to navigate a fragmenting world.

An award for Aurora Mobile's CEO reveals a bigger story: how GBA tech firms are building the AI tools for the next wave of global digital commerce.

Final Phase 1b data for Kodiak Sciences' KSI-101 suggests a potential breakthrough for macular edema, a condition lacking dedicated biologic therapies.

A new AI-driven approach to cancer therapy promises to breach the blood-brain barrier, offering hope for treating aggressive tumors where others have failed.